Drug Trial Radar · NCT07167966
Alzheimer's Tau Platform: Regimen A - AADvac1
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
450
Planned (sponsor's estimate)
Start
Nov 3, 2026
Primary completion
Aug 31, 2028
Study completion Aug 31, 2028
Sponsor
- Lead sponsor
- Paul S. AisenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Axon Neuroscience SE; University of California, San Francisco; Massachusetts General Hospital; Alzheimer's Therapeutic Research Institute; Alzheimer's Clinical Trials Consortium; National Institute on Aging (NIA)
- First posted
- Sep 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.
Conditions
- Preclinical Alzheimer's Disease
- Prodromal Alzheimer's Disease
- Alzheimer Disease
Interventions
AADvac1Drug
Subcutaneous injection of AADvac1
DonanemabDrug
Active comparator: intravenous infusion of donanemab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of brain tau deposition as measured by tau positron emission tomography (PET)Time frame: 0, 6, 18 and 30 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Banner Alzheimer's Institute
Phoenix, Arizona
University of California, San Francisco (UCSF), Memory and Aging Center
San Francisco, California
University of Kentucky Sanders Brown Center on Aging
Lexington, Kentucky
Brigham and Women's Hospital, Center for Alzheimer's Research and Treatment
Boston, Massachusetts
Butler Hospital Memory and Aging Program
Providence, Rhode Island
Vanderbilt University Medical Center
Nashville, Tennessee
Harborview Medical Center, University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.